The effect of colchicine in patients with covid 19

The effectiveness of colchicine in the incidence of pulmonary complications after COVID-19 infection: a randomized clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20251112067972N1

Enrollment

100

Registered

2026-04-23

Start date

2026-01-26

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 disease. COVID-19, virus identified /Other viral pneumonia

Interventions

Intervention 1: Intervention group: In the intervention group, after recovering from the acute phase, they will receive colchicine 0.5 mg twice a day for a period of one month. After the 3-month perio

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients who have been clinically, radiologically and PCR confirmed to have COVID-19 Age above 18 years Informed written consent

Exclusion criteria

Exclusion criteria: History of hypersensitivity to colchicine Pregnancy or lactation Patients with severe renal impairment (creatinine clearance [CrCl] 5 times the upper limit of normal [ULN]) Patients with hematologic dyscrasias, absolute neutrophil count < 1,000/mm³ or platelet count < 50,000/mm³ Patients with a history of severe heart failure Severe diarrhea, diverticulitis, or bowel perforation Patients unable to tolerate oral intake Patient demise Concomitant use of medications with contraindications to colchicine

Design outcomes

Primary

Measure	Time frame
Investigating changes in pulmonary fibrosis in CT scan of patients with covid-19. Timepoint: CT scan evaluation of patients' lungs 3 months later. Method of measurement: Investigation of lesions in lung CT scan.;Investigating changes in pulmonary bronchiectasis in CT scan of patients with covid-19. Timepoint: CT scan evaluation of patients' lungs 3 months later. Method of measurement: Investigation of lesions in lung CT scan.;Investigating changes in bronchitis in CT scan of patients with covid-19. Timepoint: CT scan evaluation of patients' lungs 3 months later. Method of measurement: Investigation of lesions in lung CT scan.;Investigating changes in cavitary lesions and air retention in CT scan of patients with covid-19. Timepoint: CT scan evaluation of patients' lungs 3 months later. Method of measurement: Investigation of lesions in lung CT scan.;Investigating changes in air retention in CT scan of patients with covid-19. Timepoint: CT scan evaluation of patients' lungs 3 months later. Method of measurement: Investigation of lesions in lung CT scan.	—

Measure

Time frame

Investigating changes in pulmonary fibrosis in CT scan of patients with covid-19. Timepoint: CT scan evaluation of patients' lungs 3 months later. Method of measurement: Investigation of lesions in lung CT scan.;Investigating changes in pulmonary bronchiectasis in CT scan of patients with covid-19. Timepoint: CT scan evaluation of patients' lungs 3 months later. Method of measurement: Investigation of lesions in lung CT scan.;Investigating changes in bronchitis in CT scan of patients with covid-19. Timepoint: CT scan evaluation of patients' lungs 3 months later. Method of measurement: Investigation of lesions in lung CT scan.;Investigating changes in cavitary lesions and air retention in CT scan of patients with covid-19. Timepoint: CT scan evaluation of patients' lungs 3 months later. Method of measurement: Investigation of lesions in lung CT scan.;Investigating changes in air retention in CT scan of patients with covid-19. Timepoint: CT scan evaluation of patients' lungs 3 months later. Method of measurement: Investigation of lesions in lung CT scan.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFateme Alizadeh moosavi

Sabzevar University of Medical Sciences

AlizademoosaviF01@medsab.ac.ir+98 51 4465 1300

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026